Detalles de la búsqueda
1.
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med
; 390(11): 994-1008, 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38477987
2.
Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways.
J Biol Chem
; 300(4): 105784, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38401844
3.
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med
; 384(11): 1028-1037, 2021 03 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33730455
4.
Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation.
J Immunol
; 208(5): 1248-1258, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35173033
5.
Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
Blood
; 137(4): 443-455, 2021 01 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33507296
6.
Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry.
Ann Hematol
; 102(7): 1637-1644, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37199789
7.
Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case-control study in the International PNH Registry.
Ann Hematol
; 102(11): 2979-2988, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37668788
8.
Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Eur J Haematol
; 109(3): 197-204, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35390189
9.
Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita.
Br J Haematol
; 193(3): 669-673, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32744739
10.
Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1.
J Immunol
; 202(7): 2082-2094, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30745459
11.
Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation.
Haematologica
; 105(5): 1223-1231, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31582549
12.
Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.
Blood
; 129(8): 970-980, 2017 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28028023
13.
Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction.
Blood
; 139(9): 1418-1422, 2022 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34875027
14.
Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)-a report on phase III.
Ann Hematol
; 98(7): 1547-1559, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31115593
15.
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med
; 373(11): 1032-9, 2015 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26352814
16.
Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay.
Transfusion
; 58(12): 2992-3002, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30367826
17.
First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012.
Am J Hematol
; 93(5): 643-648, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29498107
18.
Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.
J Immunol
; 196(2): 866-76, 2016 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26643478
19.
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.
Ann Hematol
; 96(2): 171-181, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27837250
20.
Response to Comment on "Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1".
J Immunol
; 203(8): 2029-2030, 2019 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31591258